Mutated NPM1 and FLT3-ITD are now well-validated AML MRD targets [17, 27–31], and this IDH2-mutated cohort was further studied by dividing into two subgroups based on whether they also had either of these two mutations reported at initial diagnosis. Here, IDH2 is linked to acute myeloid leukemia.